2026.07.02

Another patent granted. Another step in building global protection for Genomtec’s molecular diagnostics technology

We are pleased to share that Genomtec has received a decision from the United States Patent and Trademark Office (USPTO) granting a patent for ...
2026.06.03

Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development

Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and ...
2026.05.19

Launch of the public offering of Genomtec shares to raise funds for the finalization of the M&A process and the commercialization of Genomtec ID and OncoSNAAT® technologies

Genontec S.A. announced the launch of a public offering of shares by its principal shareholder, 5HT Family Foundation, through an accelerated ...
2026.03.19

Genomtec plans to issue shares. The proceeds will be used to support the M&A process and commercialize projects. The company has concluded an investment agreement with a key shareholder.

Genomtec S.A. on April 13, 2026, at which the Shareholders will vote on an increase in the Company’s share capital through the issue of up to 2 ...
2026.02.12

Genomtec lines up technology trials with potential Asian partners during M&A efforts

Genomtec S.A. started key preparatory activities related to planned testing of Genomtec diagnostic devices in Asia. These activities are directly ...
2025.07.31

Genomtec’s Supervisory Board appointed Leroy Huntley to the Company’s Management Board

Genomtec S.A. announced the appointment of Mr. Leroy Huntley to the Company’s Management Board on July 30, 2025, with effect from August 1, ...